Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases
Summary
These funds position us well to independently advance several precision immunology programs and potentially add additional assets to our pipeline," said Martin Babler, president and chief executive officer of Alumis. Beyond ESK-001, Alumis is using its data analytics and research capabilities to build a pipeline from internal and external sources focused on delivering precision immunology therapies impacting the causal drivers of multiple autoimmune disease indications. "Alumis’ unique approach of combining a novel precision analytics platform with deep experience in immunology pathophysiology and a proven track record of developing and commercializing novel drugs holds significant promise for the future treatment of patients with autoimmune disease," said Dr. Colowick. "Alumis is a perfect fit for our mission to support world class teams focusing on addressing the most important unmet medical needs by leveraging the convergence of technology and biology. The company’s name change to Alumis ("alumer" for "lighten/enlightened" and "immunis" for "immunology") is reflective of the transformation of the organization and overall vision to provide meaningful therapeutic solutions for people with autoimmune disease.